DK1633748T3 - Quinolinfrtibsyrt dom phosphodiesteraseinhibitorer - Google Patents

Quinolinfrtibsyrt dom phosphodiesteraseinhibitorer

Info

Publication number: DK1633748T3
Authority: DK; Denmark
Prior art keywords: quinoline; fatty acid; free fatty; phosphodiesterase inhibitors; acid phosphodiesterase
Prior art date: 2003-05-21

Application number

DK04733799T

Other languages

Danish (da)

English (en)

Inventor

Ian Robert Baldwin

Michael David Barker

Anthony William Dean

Colin David Eldred

Brian Evans

Sharon Lisa Gough

Stephen Barry Guntrip

Julie Nicole Hamblin

Stuart Holman

Paul Jones

Mika Kristian Lindvall

Christopher James Lunniss

Tracy Jane Redfern

Alison Judith Redgrave

John Edward Robinson

Michael Woodrow

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-21

Filing date

2004-05-19

Publication date

2008-06-30

2003-05-21 Priority claimed from GB0311688A external-priority patent/GB0311688D0/en

2003-11-10 Priority claimed from GB0326187A external-priority patent/GB0326187D0/en

2004-05-19 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-06-30 Application granted granted Critical

2008-06-30 Publication of DK1633748T3 publication Critical patent/DK1633748T3/da

Links

229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 title 1
229930195729 fatty acid Natural products 0.000 title 1
239000000194 fatty acid Substances 0.000 title 1
150000004665 fatty acids Chemical class 0.000 title 1
239000002571 phosphodiesterase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK04733799T 2003-05-21 2004-05-19 Quinolinfrtibsyrt dom phosphodiesteraseinhibitorer DK1633748T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0311688A GB0311688D0 (en)	2003-05-21	2003-05-21	Compounds
GB0326187A GB0326187D0 (en)	2003-11-10	2003-11-10	Compounds
PCT/EP2004/005494 WO2004103998A1 (en)	2003-05-21	2004-05-19	Quinoline derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number	Publication Date
DK1633748T3 true DK1633748T3 (da)	2008-06-30

Family

ID=33477765

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08152215.3T DK1944305T3 (da)	2003-05-21	2004-05-19	Quinolinderivater som phosphodiesteraseinhibitorer
DK04733799T DK1633748T3 (da)	2003-05-21	2004-05-19	Quinolinfrtibsyrt dom phosphodiesteraseinhibitorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK08152215.3T DK1944305T3 (da)	2003-05-21	2004-05-19	Quinolinderivater som phosphodiesteraseinhibitorer

Country Status (30)

Country	Link
US (4)	US7566786B2 (de)
EP (2)	EP1633748B1 (de)
JP (1)	JP4625460B2 (de)
KR (1)	KR101144548B1 (de)
CN (1)	CN1823063B (de)
AR (1)	AR044401A1 (de)
AT (2)	ATE529421T1 (de)
AU (1)	AU2004240759B2 (de)
BR (1)	BRPI0410477A (de)
CA (1)	CA2526228C (de)
CO (1)	CO5700780A2 (de)
CY (2)	CY1108094T1 (de)
DE (1)	DE602004012260T2 (de)
DK (2)	DK1944305T3 (de)
EG (1)	EG24774A (de)
ES (2)	ES2374850T3 (de)
HR (2)	HRP20080236T3 (de)
IL (1)	IL171726A (de)
IS (1)	IS2581B (de)
MA (1)	MA27808A1 (de)
MX (1)	MXPA05012466A (de)
NO (1)	NO330754B1 (de)
NZ (1)	NZ543554A (de)
PL (2)	PL1633748T3 (de)
PT (2)	PT1633748E (de)
RU (1)	RU2335493C2 (de)
SI (2)	SI1944305T1 (de)
TW (1)	TWI328009B (de)
WO (1)	WO2004103998A1 (de)
ZA (1)	ZA200509319B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0316290D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0425572D0 (en) *	2004-11-19	2004-12-22	Glaxo Group Ltd	1,7-Naphthyridines
EP1841780B1 (de)	2005-01-10	2011-07-27	Glaxo Group Limited	Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
GB0503955D0 (en) *	2005-02-25	2005-04-06	Glaxo Group Ltd	Novel compounds
GB0505621D0 (en) *	2005-03-18	2005-04-27	Glaxo Group Ltd	Novel compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
EP1940767A2 (de) *	2005-09-07	2008-07-09	Plexxikon, Inc.	Ppar-aktive verbindungen
GB0521563D0 (en)	2005-10-21	2005-11-30	Glaxo Group Ltd	Novel compounds
PE20071068A1 (es)	2005-12-20	2007-12-13	Glaxo Group Ltd	Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
BRPI0708337A2 (pt) *	2006-02-28	2011-05-24	Helicon Therapeutics Inc	pipirazinas terapêutica como inibidores pde4
US8927546B2 (en)	2006-02-28	2015-01-06	Dart Neuroscience (Cayman) Ltd.	Therapeutic piperazines
WO2007103554A1 (en) *	2006-03-08	2007-09-13	Amgen Inc.	Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
GB0605462D0 (en) *	2006-03-17	2006-04-26	Glaxo Group Ltd	Novel compounds
KR20090003349A (ko)	2006-04-20	2009-01-09	글락소 그룹 리미티드	화합물
NZ572381A (en) *	2006-04-28	2011-01-28	Shionogi & Co	Amine derivative having npy y5 receptor antagonist activity
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
CL2007001829A1 (es)	2006-06-23	2008-01-25	Smithkline Beecham Corp	P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
KR20090075714A (ko)	2006-10-30	2009-07-08	노파르티스 아게	소염제로서의 헤테로시클릭 화합물
TW200829555A (en) *	2006-11-10	2008-07-16	Astrazeneca Ab	Chemical compounds
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
EP2231642B1 (de)	2008-01-11	2013-10-23	Novartis AG	Pyrimidine als kinasehemmer
CN102137858B (zh)	2008-05-23	2014-07-23	潘米拉制药有限责任公司	5-脂氧合酶-活化蛋白抑制剂
JP5502858B2 (ja)	2008-06-05	2014-05-28	グラクソグループリミテッド	Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2010042163A2 (en) *	2008-10-06	2010-04-15	The Johns Hopkins University	Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
JP2012513464A (ja) *	2008-12-23	2012-06-14	ザトラスティーズオブコロンビアユニヴァーシティインザシティオブニューヨーク	ホスホジエステラーゼ阻害剤及びその使用
MX2011007499A (es)	2009-01-13	2011-08-04	Glaxo Group Ltd	Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
WO2010094643A1 (en)	2009-02-17	2010-08-26	Glaxo Group Limited	Quinoline derivatives and their uses for rhinitis and urticaria
EP2406255B1 (de)	2009-03-09	2015-04-29	Glaxo Group Limited	4-oxadiazol-2-ylindazole als inhibitoren von pi3-kinasen
WO2010102968A1 (en)	2009-03-10	2010-09-16	Glaxo Group Limited	Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en)	2009-03-17	2010-09-23	Glaxo Group Limited	Pyrimidine derivatives used as itk inhibitors
WO2010107957A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107958A1 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520683A (ja)	2009-03-19	2012-09-10	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
CA2755773A1 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
MX2011010072A (es)	2009-03-27	2011-10-06	Merck Sharp & Dohme	Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
WO2010111471A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120010272A1 (en)	2009-03-27	2012-01-12	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411520A2 (de)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid)
JP2012524755A (ja)	2009-04-24	2012-10-18	グラクソグループリミテッド	Ｃｒａｃチャネル阻害剤としてのｎ−ピラゾリルカルボキサミド
EP2421834A1 (de)	2009-04-24	2012-02-29	Glaxo Group Limited	Pyrazol- und triazolcarbonsäureamide als inhibitoren des crac-kanals
AR076435A1 (es)	2009-04-30	2011-06-08	Glaxo Group Ltd	Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
JP2013512880A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
JP2013512878A (ja)	2009-12-03	2013-04-18	グラクソグループリミテッド	新規化合物
WO2011067365A1 (en)	2009-12-03	2011-06-09	Glaxo Group Limited	Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011110575A1 (en)	2010-03-11	2011-09-15	Glaxo Group Limited	Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
WO2011143106A1 (en)	2010-05-10	2011-11-17	Gilead Sciences, Inc.	Bi - functional pyrazolopyridine compounds
NZ603136A (en)	2010-05-10	2014-11-28	Gilead Sciences Inc	Bifunctional quinoline derivatives
JP5876051B2 (ja)	2010-09-08	2016-03-02	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
RS54286B1 (sr)	2010-09-08	2016-02-29	Glaxosmithkline Intellectual Property Development Limited	Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
WO2012035055A1 (en)	2010-09-17	2012-03-22	Glaxo Group Limited	Novel compounds
EP2630126B1 (de)	2010-10-21	2015-01-07	Glaxo Group Limited	Pyrazolverbindungen gegen allergie-, immun- und entzündungserkrankungen
WO2012052459A1 (en)	2010-10-21	2012-04-26	Glaxo Group Limited	Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
US20130225524A1 (en) *	2010-11-05	2013-08-29	Deping Chai	Chemical Compounds
AU2012220572A1 (en)	2011-02-25	2013-08-29	Irm Llc	Compounds and compositions as trk inhibitors
WO2012122011A2 (en) *	2011-03-04	2012-09-13	Glaxosmithkline Llc	Amino-quinolines as kinase inhibitors
GB201104153D0 (en)	2011-03-11	2011-04-27	Glaxo Group Ltd	Novel compounds
EP2683716A1 (de)	2011-03-11	2014-01-15	Glaxo Group Limited	Pyrido[3,4-b]pyrazinderivate als syk-hemmer
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
MX344308B (es) *	2011-11-03	2016-12-13	Merck Sharp & Dohme	Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
TWI592417B (zh)	2012-09-13	2017-07-21	葛蘭素史克智慧財產發展有限公司	胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh)	2012-09-13	2014-07-01	Glaxosmithkline Llc	作為激酶抑制劑之胺基－喹啉類
CA3217159A1 (en)	2013-02-01	2014-08-07	Wellstat Therapeutics Corporation	Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
TWI630203B (zh)	2013-02-21	2018-07-21	葛蘭素史克智慧財產發展有限公司	做為激酶抑制劑的喹唑啉類
JP2016537327A (ja)	2013-10-17	2016-12-01	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
RU2016112266A (ru)	2013-10-17	2017-11-20	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Ингибитор PI3K для лечения респираторного заболевания
WO2015173701A2 (en)	2014-05-12	2015-11-19	Glaxosmithkline Intellectual Property (No. 2) Limited	Pharmaceutical compositions for treating infectious diseases
US10100015B2 (en) *	2015-03-24	2018-10-16	Shanghai Yingli Pharmaceutical Co., Ltd.	Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
JP2019524792A (ja)	2016-08-08	2019-09-05	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	化合物
AU2017382294A1 (en) *	2016-12-22	2019-08-01	Abbvie Inc.	Compositions and methods of enhancing or augmenting type I IFN production
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
CN111875594A (zh) *	2020-07-21	2020-11-03	中国药科大学	具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
CN120457119A (zh) *	2023-01-17	2025-08-08	瑞石生物医药有限公司	Pde4抑制剂、其制备方法及其在医药上的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2340735A1 (fr) *	1976-02-11	1977-09-09	Roussel Uclaf	Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE46886B1 (en)	1977-05-17	1983-10-19	Allen & Hanburys Ltd	Aminoalkyl-benzene derivatives
EP0048005A3 (de) *	1980-09-17	1983-01-19	ALFA-Institut für hauswirtschaftliche Produkt- und Verfahrens-Entwicklung GmbH	Vorrichtung zum Stapeln von Geschirr
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
US5215999A (en) *	1990-03-28	1993-06-01	Otsuka Pharmaceutical Co., Ltd.	Quinoline derivative and antiulcer agent containing said quinoline derivative
US5214191A (en)	1990-05-22	1993-05-25	Cortech, Inc.	Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
MX9200299A (es)	1991-02-07	1992-12-01	Roussel Uclaf	Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
DE69435280D1 (de)	1993-03-10	2010-04-15	Glaxosmithkline Llc	Phosphodiesterase des menschlichen Gehirns und Screening-Verfahren
FR2705346B1 (fr)	1993-05-18	1995-08-11	Union Pharma Scient Appl	Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
DK122693D0 (da)	1993-10-29	1993-10-29	Hempels Skibsfarve Fab J C	Marin struktur
DK0957087T3 (da)	1994-06-15	2003-03-24	Wellcome Found	Intermediater, der er anvendelige til fremstilling af enzym-inhibitorer
WO1997044322A1 (en) *	1996-05-20	1997-11-27	Darwin Discovery Limited	Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
DE69716916T2 (de)	1996-07-13	2003-07-03	Glaxo Group Ltd., Greenford	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
AU733551B2 (en)	1996-09-25	2001-05-17	Astrazeneca Ab	Qinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9712761D0 (en)	1997-06-17	1997-08-20	Chiroscience Ltd	Quinolines and their therapeutic use
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
RU2220960C2 (ru)	1997-12-22	2004-01-10	Фармация Энд Апджон Компани	4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
AU6159499A (en)	1998-09-29	2000-04-17	Wyeth Holdings Corporation	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
HUP0103520A3 (en)	1998-09-29	2003-01-28	Wyeth Holdings Corp Madison	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
MY121142A (en)	1999-02-23	2005-12-30	Smithkline Beecham Corp	Controlled release formulation for treating copd
ES2222189T3 (es)	1999-03-15	2005-02-01	Abbott Laboratories	Macrolidos sustituidos en 6-o con una actividad antibacteriana.
GB0008485D0 (en) *	2000-04-07	2000-05-24	Glaxo Group Ltd	Pharmaceutical compositions
US20020052312A1 (en)	2000-05-30	2002-05-02	Reiss Theodore F.	Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
NZ523749A (en)	2000-07-26	2005-03-24	Smithkline Beecham P	Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6576644B2 (en) *	2000-09-06	2003-06-10	Bristol-Myers Squibb Co.	Quinoline inhibitors of cGMP phosphodiesterase
IL155093A0 (en)	2000-09-29	2003-10-31	Glaxo Group Ltd	Morpholin-acetamide derivatives for the treatment on inflammatory diseases
GB0023918D0 (en)	2000-09-29	2000-11-15	King S College London	Antiparasitic compounds
US20020193393A1 (en)	2001-03-07	2002-12-19	Michel Pairet	Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10110772A1 (de)	2001-03-07	2002-09-12	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
AU2001295791A1 (en)	2000-11-02	2002-05-15	Astrazeneca Ab	4-substituted quinolines as antitumor agents
AU2002210714A1 (en)	2000-11-02	2002-06-11	Astrazeneca Ab	Substituted quinolines as antitumor agents
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
GB0104422D0 (en)	2001-02-22	2001-04-11	Glaxo Group Ltd	Quinoline derivative
SE0101675D0 (sv) *	2001-05-11	2001-05-11	Astrazeneca Ab	Novel composition
UY27304A1 (es)	2001-05-24	2002-12-31	Avanir Pharmaceuticals	Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
JP2003005355A (ja)	2001-06-20	2003-01-08	Fuji Photo Film Co Ltd	電子線又はｘ線用ネガ型レジスト組成物
GB0118373D0 (en)	2001-07-27	2001-09-19	Glaxo Group Ltd	Novel therapeutic method
CA2464214C (en)	2001-10-22	2011-02-08	The Research Foundation Of State University Of New York	Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
EP1451156A4 (de)	2001-11-27	2005-05-25	Merck & Co Inc	4-aminochinolinverbindungen
AR037641A1 (es)	2001-12-05	2004-11-17	Tularik Inc	Moduladores de inflamacion
WO2003064431A2 (en)	2002-01-29	2003-08-07	Glaxo Group Limited	Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
EA011581B1 (ru)	2002-06-20	2009-04-28	Биовитрум Аб (Пабл)	Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы
WO2004067513A1 (en)	2003-01-27	2004-08-12	Oy Juvantia Pharma Ltd	Antagonists for alpha-2 adrenoceptors
CA2518398A1 (en)	2003-03-10	2004-09-23	Schering Corporation	Heterocyclic kinase inhibitors: methods of use and synthesis
GB0322722D0 (en) *	2003-09-27	2003-10-29	Glaxo Group Ltd	Compounds
GB0322726D0 (en) *	2003-09-27	2003-10-29	Glaxo Group Ltd	Compounds

2004
- 2004-05-14 TW TW093113762A patent/TWI328009B/zh not_active IP Right Cessation
- 2004-05-19 AT AT08152215T patent/ATE529421T1/de active
- 2004-05-19 EP EP04733799A patent/EP1633748B1/de not_active Expired - Lifetime
- 2004-05-19 MX MXPA05012466A patent/MXPA05012466A/es active IP Right Grant
- 2004-05-19 PL PL04733799T patent/PL1633748T3/pl unknown
- 2004-05-19 NZ NZ543554A patent/NZ543554A/en not_active IP Right Cessation
- 2004-05-19 US US10/557,079 patent/US7566786B2/en not_active Expired - Fee Related
- 2004-05-19 BR BRPI0410477-3A patent/BRPI0410477A/pt not_active IP Right Cessation
- 2004-05-19 SI SI200431802T patent/SI1944305T1/sl unknown
- 2004-05-19 AR ARP040101734A patent/AR044401A1/es unknown
- 2004-05-19 ES ES08152215T patent/ES2374850T3/es not_active Expired - Lifetime
- 2004-05-19 KR KR1020057022135A patent/KR101144548B1/ko not_active Expired - Fee Related
- 2004-05-19 PT PT04733799T patent/PT1633748E/pt unknown
- 2004-05-19 WO PCT/EP2004/005494 patent/WO2004103998A1/en not_active Ceased
- 2004-05-19 EP EP08152215A patent/EP1944305B1/de not_active Expired - Lifetime
- 2004-05-19 HR HR20080236T patent/HRP20080236T3/xx unknown
- 2004-05-19 DE DE602004012260T patent/DE602004012260T2/de not_active Expired - Lifetime
- 2004-05-19 DK DK08152215.3T patent/DK1944305T3/da active
- 2004-05-19 AU AU2004240759A patent/AU2004240759B2/en not_active Ceased
- 2004-05-19 DK DK04733799T patent/DK1633748T3/da active
- 2004-05-19 CN CN2004800206511A patent/CN1823063B/zh not_active Expired - Fee Related
- 2004-05-19 AT AT04733799T patent/ATE388148T1/de active
- 2004-05-19 PL PL08152215T patent/PL1944305T3/pl unknown
- 2004-05-19 ES ES04733799T patent/ES2301993T3/es not_active Expired - Lifetime
- 2004-05-19 SI SI200430691T patent/SI1633748T1/sl unknown
- 2004-05-19 RU RU2005135016/04A patent/RU2335493C2/ru not_active IP Right Cessation
- 2004-05-19 PT PT08152215T patent/PT1944305E/pt unknown
- 2004-05-19 CA CA2526228A patent/CA2526228C/en not_active Expired - Fee Related
- 2004-05-19 JP JP2006529889A patent/JP4625460B2/ja not_active Expired - Fee Related
2005
- 2005-10-31 IS IS8110A patent/IS2581B/is unknown
- 2005-11-02 IL IL171726A patent/IL171726A/en not_active IP Right Cessation
- 2005-11-15 EG EGNA2005000730 patent/EG24774A/xx active
- 2005-11-16 NO NO20055421A patent/NO330754B1/no not_active IP Right Cessation
- 2005-11-16 CO CO05116284A patent/CO5700780A2/es active IP Right Grant
- 2005-11-17 ZA ZA200509319A patent/ZA200509319B/xx unknown
- 2005-11-21 MA MA28611A patent/MA27808A1/fr unknown
2006
- 2006-02-08 US US11/349,701 patent/US20070049570A1/en not_active Abandoned
- 2006-02-08 US US11/349,677 patent/US7572915B2/en not_active Expired - Fee Related
2008
- 2008-05-23 CY CY20081100534T patent/CY1108094T1/el unknown
2009
- 2009-05-29 US US12/474,324 patent/US20090312325A1/en not_active Abandoned
2011
- 2011-12-20 HR HR20110957T patent/HRP20110957T1/hr unknown
2012
- 2012-01-11 CY CY20121100032T patent/CY1112232T1/el unknown

Also Published As

Publication number	Publication date
BRPI0410477A (pt)	2006-05-30
HRP20080236T3 (en)	2008-06-30
EP1944305B1 (de)	2011-10-19
AR044401A1 (es)	2005-09-14
PT1633748E (pt)	2008-05-20
NO20055421L (no)	2005-12-20
AU2004240759A1 (en)	2004-12-02
ES2301993T3 (es)	2008-07-01
IL171726A (en)	2013-07-31
HK1118274A1 (en)	2009-02-06
US7572915B2 (en)	2009-08-11
PL1633748T3 (pl)	2008-07-31
WO2004103998A1 (en)	2004-12-02
IS2581B (is)	2010-02-15
RU2335493C2 (ru)	2008-10-10
EP1633748B1 (de)	2008-03-05
EG24774A (en)	2010-08-19
MXPA05012466A (es)	2006-01-30
MA27808A1 (fr)	2006-03-01
AU2004240759B2 (en)	2010-03-04
CN1823063A (zh)	2006-08-23
ZA200509319B (en)	2007-02-28
HK1092458A1 (en)	2007-02-09
CN1823063B (zh)	2010-07-14
KR20060015278A (ko)	2006-02-16
IS8110A (is)	2005-10-31
ATE529421T1 (de)	2011-11-15
ES2374850T3 (es)	2012-02-22
ATE388148T1 (de)	2008-03-15
DE602004012260T2 (de)	2009-03-12
NO330754B1 (no)	2011-07-04
TW200500358A (en)	2005-01-01
NO20055421D0 (no)	2005-11-16
KR101144548B1 (ko)	2012-05-11
CY1112232T1 (el)	2015-12-09
DE602004012260D1 (de)	2008-04-17
CA2526228A1 (en)	2004-12-02
PT1944305E (pt)	2012-01-11
US20070142373A1 (en)	2007-06-21
EP1944305A1 (de)	2008-07-16
CY1108094T1 (el)	2014-02-12
HRP20110957T1 (hr)	2012-01-31
SI1944305T1 (sl)	2012-02-29
CO5700780A2 (es)	2006-11-30
DK1944305T3 (da)	2012-01-30
JP2007501264A (ja)	2007-01-25
EP1633748A1 (de)	2006-03-15
TWI328009B (en)	2010-08-01
NZ543554A (en)	2008-09-26
US20060178416A1 (en)	2006-08-10
JP4625460B2 (ja)	2011-02-02
RU2005135016A (ru)	2006-06-27
US20090312325A1 (en)	2009-12-17
SI1633748T1 (sl)	2008-08-31
PL1944305T3 (pl)	2012-03-30
US20070049570A1 (en)	2007-03-01
CA2526228C (en)	2010-08-03
US7566786B2 (en)	2009-07-28

Publication	Publication Date	Title
DK1692242T3 (da)	2007-08-27	Viskoelastisk syre
ATE383329T1 (de)	2008-01-15	Biaryloxymethylarenecarbonsäure
NO20054852D0 (no)	2005-10-20	GFAT inhibitorer
DE602004018837D1 (de)	2009-02-12	Ptidase-iv-inhibitoren
NO20055680D0 (no)	2005-12-01	Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
ATE388148T1 (de)	2008-03-15	Chinolinderivate als phosphodiesterase inhibitoren
ATE443054T1 (de)	2009-10-15	Cyano-pyrrolidine als dpp-iv inhibitoren
DK1660431T3 (da)	2009-06-15	Phenoxyeddikesyrederivater
FR2862175B1 (fr)	2007-05-18	Assistance-annuaire
DE60320933D1 (de)	2008-06-26	Rho-kinase inhibitoren
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
DE602004021001D1 (de)	2009-06-18	Fettsäuredesaturasen aus primula
ATE411306T1 (de)	2008-10-15	Biarylsulfonamide als mmp-inhibitoren
EP1660436A4 (de)	2006-11-22	Cathepsininhibitoren
DE602004011548D1 (de)	2008-03-13	4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer
PT1401828E (pt)	2006-08-31	Compostos de n-formil-hidroxilamina como inibidores de pdf
DE502004006055D1 (de)	2008-03-13	6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
NO20054747D0 (no)	2005-10-14	Fosforsyreester-demulgerende sammensetning
EP1570847A4 (de)	2008-10-08	Phosphodiesterase 10a-hemmer
NO20043400L (no)	2004-09-17	Fremgangsmater for nukleinsyreamplifisering
DE60328233D1 (de)	2009-08-13	Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
IS7963A (is)	2005-07-28	Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
DE50306664D1 (de)	2007-04-12	Zimtsäureamide
DE10356170B8 (de)	2005-12-29	Wälzkörper-Haltevorrichtung